|
MechanismMAO-B inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date21 Feb 2005 |
评估低浓度硫酸阿托品滴眼液在中国健康成年受试者中单/多次给药的安全性、耐受性和药代动力学特征的I期临床研究
[Translation] A phase I clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of single/multiple administrations of low-concentration atropine sulfate eye drops in healthy Chinese adult subjects
主要目的:1)评价低浓度硫酸阿托品滴眼液在中国健康成年受试者中单/多次滴眼给药的安全性和耐受性。
次要目的:1)评价低浓度硫酸阿托品滴眼液在中国健康成年受试者中单/多次滴眼给药的血浆药代动力学特征。
[Translation] Primary objective: 1) To evaluate the safety and tolerability of single/multiple eye drops of low-concentration atropine sulfate eye drops in healthy Chinese adult subjects.
Secondary objective: 1) To evaluate the plasma pharmacokinetic characteristics of single/multiple eye drops of low-concentration atropine sulfate eye drops in healthy Chinese adult subjects.
/ CompletedNot Applicable 应用左旋多巴诱导的运动波动的有效性和安全性的多中心、随机、双盲、安慰剂平行对照临床研究
[Translation] A multicenter, randomized, double-blind, placebo-controlled clinical study on the efficacy and safety of levodopa-induced motor fluctuations
验证甲磺酸雷沙吉兰口腔崩解片治疗应用L-多巴治疗但运动症状有波动的原发性帕金森病患者有效性和安全性
[Translation] To verify the efficacy and safety of rasagiline mesylate orally disintegrating tablets in the treatment of patients with primary Parkinson's disease who have motor fluctuations despite L-dopa treatment
/ Not yet recruitingPhase 1 [Translation] Pharmacokinetics of pilocarpine hydrochloride eye drops in humans
评价盐酸毛果芸香碱滴眼液在中国健康受试者中的药代动力学特征。
[Translation] To evaluate the pharmacokinetic characteristics of pilocarpine hydrochloride eye drops in Chinese healthy subjects.
100 Clinical Results associated with Tianjin Kingyork Group Hebei Univision Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Tianjin Kingyork Group Hebei Univision Pharmaceutical Co., Ltd.
100 Deals associated with Tianjin Kingyork Group Hebei Univision Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Tianjin Kingyork Group Hebei Univision Pharmaceutical Co., Ltd.